Seer, which is developing next-generation proteome analysis tests for biomedical research, announced terms for its IPO on Monday. The Redwood City, CA-based company plans to raise $150 million by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback